These findings confirm the role of SGLT2i, incretin-based therapies, and finerenone in cardiorenal risk reduction across established high-risk groups, including T2D and CKD, and extend benefits to newer populations, including acute HF and post-MI for SGLT2i, and HFpEF with obesity for incretin-based therapies. This evidence concerns the gene GCG and type 2 diabetes mellitus.